Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121588 · ClinicalTrials.gov registry record · Phase 1
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01121588 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 44 participants.
The verdict
NCT01121588, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
Interventions
- DRUG Crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2023-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121588
The ClinicalTrials.gov registry entry for NCT01121588 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crizotinib is the first listed.
NCT01121588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121588 about?
NCT01121588 is a clinical study titled "Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)". This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
What is the current status of trial NCT01121588?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2011-03-22. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT01121588?
The interventions under investigation include: Crizotinib (DRUG).
Who is sponsoring clinical trial NCT01121588?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.